Sinocelltech Group Limited, a biopharmaceutical company, engages in the research and development and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anpingxi, an antibody drug and anti-tumor product; Anjiayin for the treatment of hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and SCTV01C and SCTV01E, which are mutant strain recombinant protein vaccines. Its product pipeline includes SCT630 used for the treatment of autoimmune diseases; SCT510 for treating solid tumors; SCT-I10A, a monoclonal antibody injection, which is in phase 3 trials for the treatment of solid tumors; SCTV01 vaccine for the treatment of corona virus; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000 for the treatment of human papillomavirus, as well as SCTA01, which is in phase 2/3 clinical research trials for treating SARS COV-2. The company was founded in 2002 and is based in Beijing, China. Sinocelltech Group Limited is a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.
Metrics to compare | 688520 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688520PeersSector | |
|---|---|---|---|---|
P/E Ratio | −79.4x | −17.4x | −0.6x | |
PEG Ratio | 0.08 | −0.18 | 0.00 | |
Price/Book | −475.3x | 6.6x | 2.6x | |
Price / LTM Sales | 12.1x | 18.7x | 3.3x | |
Upside (Analyst Target) | −4.8% | 29.7% | 41.7% | |
Fair Value Upside | Unlock | −18.8% | 5.1% | Unlock |